1882 related items for PubMed ID: 16172458
1. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi.
Gobbi PG, Levis A, Chisesi T, Broglia C, Vitolo U, Stelitano C, Pavone V, Cavanna L, Santini G, Merli F, Liberati M, Baldini L, Deliliers GL, Angelucci E, Bordonaro R, Federico M, Intergruppo Italiano Linfomi.
J Clin Oncol; 2005 Dec 20; 23(36):9198-207. PubMed ID: 16172458
[Abstract] [Full Text] [Related]
2. Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfomi.
Chisesi T, Bellei M, Luminari S, Montanini A, Marcheselli L, Levis A, Gobbi P, Vitolo U, Stelitano C, Pavone V, Merli F, Liberati M, Baldini L, Bordonaro R, Pesce EA, Federico M.
J Clin Oncol; 2011 Nov 10; 29(32):4227-33. PubMed ID: 21990405
[Abstract] [Full Text] [Related]
3. MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors.
Gobbi PG, Broglia C, Levis A, La Sala A, Valentino F, Chisesi T, Sacchi S, Corbella F, Cavanna L, Iannitto E, Pavone V, Molica S, Corazza GR, Federico M.
Clin Cancer Res; 2006 Jan 15; 12(2):529-35. PubMed ID: 16428496
[Abstract] [Full Text] [Related]
4. Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244.
Hoskin PJ, Lowry L, Horwich A, Jack A, Mead B, Hancock BW, Smith P, Qian W, Patrick P, Popova B, Pettitt A, Cunningham D, Pettengell R, Sweetenham J, Linch D, Johnson PW.
J Clin Oncol; 2009 Nov 10; 27(32):5390-6. PubMed ID: 19738111
[Abstract] [Full Text] [Related]
5. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial.
Federico M, Luminari S, Iannitto E, Polimeno G, Marcheselli L, Montanini A, La Sala A, Merli F, Stelitano C, Pozzi S, Scalone R, Di Renzo N, Musto P, Baldini L, Cervetti G, Angrilli F, Mazza P, Brugiatelli M, Gobbi PG, HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial.
J Clin Oncol; 2009 Feb 10; 27(5):805-11. PubMed ID: 19124807
[Abstract] [Full Text] [Related]
6. Lomustine and melphalan cannot be replaced by cyclophosphamide and etoposide without reducing efficacy in MOPPEBVCAD chemotherapy for advanced Hodgkin's disease.
Gobbi PG, Broglia C, Bertè R, Petrilli MP, Molica S, Angrilli F, Iannitto E, Ghirardelli ML, Di Renzo N, Cavanna L, Ascari E.
Haematologica; 2000 Jul 10; 85(7):722-8. PubMed ID: 10897124
[Abstract] [Full Text] [Related]
7. Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of the German Hodgkin Study Group.
Pfreundschuh MG, Schoppe WD, Fuchs R, Pflüger KH, Loeffler M, Diehl V.
Cancer Treat Rep; 1987 Dec 10; 71(12):1203-7. PubMed ID: 2446751
[Abstract] [Full Text] [Related]
8. What is the treatment of choice for advanced-stage Hodgkin's lymphoma: ABVD, Stanford V, or BEACOPP?
Hehn ST, Miller TP.
Curr Hematol Rep; 2004 Jan 10; 3(1):17-26. PubMed ID: 14695845
[Abstract] [Full Text] [Related]
9. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD.
Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, Green MR, Gottlieb A, Peterson BA.
N Engl J Med; 1992 Nov 19; 327(21):1478-84. PubMed ID: 1383821
[Abstract] [Full Text] [Related]
10. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial.
Eich HT, Diehl V, Görgen H, Pabst T, Markova J, Debus J, Ho A, Dörken B, Rank A, Grosu AL, Wiegel T, Karstens JH, Greil R, Willich N, Schmidberger H, Döhner H, Borchmann P, Müller-Hermelink HK, Müller RP, Engert A.
J Clin Oncol; 2010 Sep 20; 28(27):4199-206. PubMed ID: 20713848
[Abstract] [Full Text] [Related]
11. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group.
Engert A, Schiller P, Josting A, Herrmann R, Koch P, Sieber M, Boissevain F, De Wit M, Mezger J, Duhmke E, Willich N, Muller RP, Schmidt BF, Renner H, Muller-Hermelink HK, Pfistner B, Wolf J, Hasenclever D, Loffler M, Diehl V, German Hodgkin's Lymphoma Study Group.
J Clin Oncol; 2003 Oct 01; 21(19):3601-8. PubMed ID: 12913100
[Abstract] [Full Text] [Related]
12. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
Sieber M, Bredenfeld H, Josting A, Reineke T, Rueffer U, Koch T, Naumann R, Boissevain F, Koch P, Worst P, Soekler M, Eich H, Müller-Hermelink HK, Franklin J, Paulus U, Wolf J, Engert A, Diehl V, German Hodgkin's Lymphoma Study Group.
J Clin Oncol; 2003 May 01; 21(9):1734-9. PubMed ID: 12721249
[Abstract] [Full Text] [Related]
13. Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial.
Advani RH, Hong F, Fisher RI, Bartlett NL, Robinson KS, Gascoyne RD, Wagner H, Stiff PJ, Cheson BD, Stewart DA, Gordon LI, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tuscano JM, Hoppe RT, Horning SJ.
J Clin Oncol; 2015 Jun 10; 33(17):1936-42. PubMed ID: 25897153
[Abstract] [Full Text] [Related]
14. Can MOPP be replaced in the treatment of advanced Hodgkin's disease?
Canellos GP.
Semin Oncol; 1990 Feb 10; 17(1 Suppl 2):2-6. PubMed ID: 1689509
[Abstract] [Full Text] [Related]
15. Combination chemotherapy plus low-dose involved-field radiotherapy for early clinical stage Hodgkin's lymphoma.
Vassilakopoulos TP, Angelopoulou MK, Siakantaris MP, Kontopidou FN, Dimopoulou MN, Kokoris SI, Kyrtsonis MC, Tsaftaridis P, Karkantaris C, Anargyrou K, Boutsis DE, Variamis E, Michalopoulos T, Boussiotis VA, Panayiotidis P, Papavassiliou C, Pangalis GA.
Int J Radiat Oncol Biol Phys; 2004 Jul 01; 59(3):765-81. PubMed ID: 15183480
[Abstract] [Full Text] [Related]
16. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease.
Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D, Tesch H, Herrmann R, Dörken B, Müller-Hermelink HK, Dühmke E, Loeffler M, German Hodgkin's Lymphoma Study Group.
N Engl J Med; 2003 Jun 12; 348(24):2386-95. PubMed ID: 12802024
[Abstract] [Full Text] [Related]
17. Efficacy of a modified Stanford V regimen in patients with advanced Hodgkin's lymphoma.
Hohaus S, Di Febo A, Storti S, Teofili L, Voso MT, Leone G.
Haematologica; 2004 Jun 12; 89(6):751-2. PubMed ID: 15194545
[Abstract] [Full Text] [Related]
18. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial.
Engert A, Franklin J, Eich HT, Brillant C, Sehlen S, Cartoni C, Herrmann R, Pfreundschuh M, Sieber M, Tesch H, Franke A, Koch P, de Wit M, Paulus U, Hasenclever D, Loeffler M, Müller RP, Müller-Hermelink HK, Dühmke E, Diehl V.
J Clin Oncol; 2007 Aug 10; 25(23):3495-502. PubMed ID: 17606976
[Abstract] [Full Text] [Related]
19. Early versus late intensification for patients with high-risk Hodgkin lymphoma-3 cycles of intensive chemotherapy plus low-dose lymph node radiation therapy versus 4 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine plus myeloablative chemotherapy with autologous stem cell transplantation: five-year results of a randomized trial on behalf of the GOELAMS Group.
Arakelyan N, Berthou C, Desablens B, de Guibert S, Delwail V, Moles MP, Quittet P, Jais JP, Colonna P, Andrieu JM, Groupe Ouest-Est d'Etude des Leucémies et Autres Maladies du Sang.
Cancer; 2008 Dec 15; 113(12):3323-30. PubMed ID: 18988286
[Abstract] [Full Text] [Related]
20. Comparison between hybrid MOPPABV and ABVD chemotherapy protocols for Hodgkin's lymphoma in public hospitals of the largest South American city: a retrospective 14-year study.
Souza EM, Baiocchi OC, Zanichelli MA, Alves AC, Oliveira JS.
Ann Hematol; 2009 Jul 15; 88(7):633-7. PubMed ID: 18998131
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
